OBJECTIVE: The objective of this study was to evaluate the occurrence of adverse effects during surfactant delivery, using a standardized protocol for administration and management of complications. STUDY DESIGN: The protocol was developed, implemented and used for 6 months. Vital signs and ventilatory parameters were prospectively recorded during the procedure. Infants were classified into three groups, based on the occurrence and severity of complications: no, minor or major. RESULT: A total of 39 infants received surfactant and 19 presented some complication: 11 minor and 8 major. Six of the major complications were episodes of severe airway obstruction (SAO) and five occurred in extreme low birth weight (ELBW) infants that had more severe lung disease before surfactant delivery. Two cases of persistent pulmonary hypertension occurred in infants with birth weight>1000 g. CONCLUSION: This study identified a high rate of SAO and provides data to support changes in the protocol, which should include faster and more robust increases in positive inspiratory pressures in ELBW infants presenting with SAO.
OBJECTIVE: The objective of this study was to evaluate the occurrence of adverse effects during surfactant delivery, using a standardized protocol for administration and management of complications. STUDY DESIGN: The protocol was developed, implemented and used for 6 months. Vital signs and ventilatory parameters were prospectively recorded during the procedure. Infants were classified into three groups, based on the occurrence and severity of complications: no, minor or major. RESULT: A total of 39 infants received surfactant and 19 presented some complication: 11 minor and 8 major. Six of the major complications were episodes of severe airway obstruction (SAO) and five occurred in extreme low birth weight (ELBW) infants that had more severe lung disease before surfactant delivery. Two cases of persistent pulmonary hypertension occurred in infants with birth weight>1000 g. CONCLUSION: This study identified a high rate of SAO and provides data to support changes in the protocol, which should include faster and more robust increases in positive inspiratory pressures in ELBW infants presenting with SAO.
Authors: Matthias C Hütten; Elke Kuypers; Daan R Ophelders; Maria Nikiforou; Reint K Jellema; Hendrik J Niemarkt; Carola Fuchs; Markus Tservistas; Roberta Razetti; Federico Bianco; Boris W Kramer Journal: Pediatr Res Date: 2015-08-31 Impact factor: 3.756
Authors: Regan E Giesinger; Kiran More; Jodie Odame; Amish Jain; Robert P Jankov; Patrick J McNamara Journal: Pediatr Res Date: 2017-10-04 Impact factor: 3.756
Authors: Jurate Panaviene; Andrea Pacheco; Christoph E Schwarz; Konstantin Grygoryev; Stefan Andersson-Engels; Eugene M Dempsey Journal: Pediatr Res Date: 2022-05-23 Impact factor: 3.953
Authors: Amish Jain; Regan E Giesinger; Shyamala Dakshinamurti; Yasser ElSayed; Robert P Jankov; Dany E Weisz; Satyan Lakshminrusimha; Souvik Mitra; Mjaye L Mazwi; Joseph Ting; Michael Narvey; Patrick J McNamara Journal: J Perinatol Date: 2022-01-11 Impact factor: 3.225